Chorioamnionitis and Proinflammatory S100A12

Impact of Chorioamnionitis on Maternal and Fetal Levels of Proinflammatory S100A12

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02996279

Acronym

S100A12

Enrollment

Registered

2016-12-19

Start date

2012-02-29

Completion date

2013-03-31

Last updated

2016-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chorioamnionitis Affecting Fetus or Newborn

Keywords

Neonate, Chorioamnionitis, S100A12

Brief summary

Histologic chorioamnionitis (HCA) may lead to the fetal inflammatory response syndrome (FIRS) and increased levels of proinflammatory molecules.

Detailed description

Histologic chorioamnionitis (HCA) may lead to the fetal inflammatory response syndrome (FIRS). The aim of this pilot study was to evaluate S100A12, a marker of innate immune activation, in mothers with or without HCA and in their infants. Concentrations of S100A12, Interleukin 6 (IL-6) and C-reactive protein (CRP) were evaluated in maternal, cord, and neonatal blood of very preterm infants. Histologic examinations of placentae and umbilical cords were performed.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

Preterm Birth

Exclusion criteria

Congenital Abnormalities

Design outcomes

Primary

Measure	Time frame	Description
S100A12 in Presence of Maternal Chorioamnionitis	1 Year	Levels of S100A12 in Maternal, Cord and Neonatal Blood in the Presence or Absence of HCA

Outcome results